Antibes

This research focuses on high-risk myelodysplastic syndromes MDS and acute myeloid leukemia with multilineage dysplasia AML-MD, conditions common in older adults with a median age of 71 years. The study aims to understand how the drug Azacitidine works and why resistance to it develops, particularly looking at its effects on cell death processes like apoptosis and autophagy. The investigation also explores new drugs that might reverse resistance to Azacitidine by targeting these cell death pathways. Participants in this observational study are adults aged 18 years or older with high-risk or intermediate 2 MDS or AML-MD who have undergone treatment with at least three to six cycles of Azacitidine. The study does not involve additional treatment but collects data to characterize molecular mechanisms of action and resistance. Researchers focus on hematological responses at three and six months and overall survival from the start of treatment and at death. During the study, participants clinical and molecular data related to their response to Azacitidine are observed and analyzed. The main outcomes include blood response measurements and survival tracking. The study is sponsored by the Centre Hospitalier Universitaire de Nice and began in 2010, with planned follow-up through September 2025. Participation involves regular monitoring without additional interventions, allowing researchers to evaluate treatment impact and resistance mechanisms over time.

Researchers are studying ways to improve how well adult patients with chronic diseases follow their treatment plans. The study aims to increase adherence to therapy by 15% over six months by using a simple, standardized, and repeated message delivered by trained healthcare professionals. This approach is designed to help patients better manage their treatments without changing their prescribed medications. In this trial, healthcare professionals provide patients with a clear 3-point message focused on boosting therapeutic adherence. This message is delivered during patient consultations after the professionals have been trained. The study uses a stepped-wedge design where some patients receive usual care before the message delivery begins, followed by an intervention period where the message is given repeatedly by various healthcare providers involved in the patients hospital care. The delivery of the message is tracked using a checklist. Participants are involved by completing a self-questionnaire about their treatment adherence, helping them engage actively in managing their care. The study measures improvements in adherence at six and twelve months, along with factors predicting better adherence, costs of care, intervention costs, and healthcare professionals satisfaction. The research will help guide better patient care practices and optimize treatment benefits while reducing healthcare resource waste.

Researchers are conducting a long-term observational study to understand how dupilumab is used and its effects in patients with Chronic Obstructive Pulmonary Disease COPD who are treated as part of routine care. This study will follow about 350 to 500 participants in multiple sites across France over 36 months, collecting detailed information on patient characteristics, safety, and patient-reported outcomes. The goal is to describe various aspects of COPD and treatment history to better characterize this patient group. Participants in this study are those newly starting dupilumab treatment for COPD, as prescribed by their doctors in line with approved guidelines. The study does not involve any additional treatment but observes the use of dupilumab over time. No placebo or comparator group is included. Data will be collected retrospectively and prospectively, covering medical history before dupilumab initiation and ongoing treatment effects during the 36-month follow-up. Throughout the study, researchers will gather detailed data on demographics, disease characteristics, lung function, exacerbations, comorbidities, and patient-reported assessments such as quality of life and symptom scores. Safety outcomes, including adverse events and reasons for stopping treatment, will be monitored. The study duration for each participant is about 36 months, allowing long-term observation of treatment and disease progression in real-world conditions.

Researchers are studying the use of capillary lactatemia to assess the severity of potentially severe polytrauma patients before they reach the hospital. Current tools like vital signs and shock scores have limitations and can be subjective. Capillary lactatemia is a simple and quick test that could help predict poor outcomes in trauma patients, similar to venous lactatemia, but has not yet been studied in this context. The study involves collecting capillary blood samples during the transfer of trauma patients to emergency facilities. These samples are analyzed to measure lactate levels at inclusion and again six hours later. The goal is to see if capillary lactate levels can improve the prediction of severe outcomes and help guide better patient management in the pre-hospital setting. Participants will be trauma patients aged 18 or older, who have suffered serious injuries like road accidents or falls over two meters and require emergency medical assistance. The study measures lactate values at two time points and monitors patient outcomes. Consent is obtained from the patient or a relative, and pregnant women can participate safely. The study runs until December 2027 and includes continuous assessment during hospital transfer and emergency care.

Peripheral arterial disease PAD and type 2 diabetes are significant health concerns. In France, over one million people have PAD and more than 3.5 million have diabetes. Screening for PAD in diabetic patients is usually done with the Toe-Brachial pressure index TBi, which is time-consuming and technically challenging. This study evaluates a new photoplethysmographic PPG method to measure the upstroke time, which could provide a faster, easier, and less expensive way to assess peripheral blood flow in diabetic patients. The study will compare the upstroke time measured by the PPG method using the POPMETRE device with the traditional TBi method in adults with type 2 diabetes. This prospective study will take place in two centers, and each participant will have their upstroke time measured by the PPG device during a vascular medicine consultation for PAD screening or follow-up. The study aims to determine how well the PPG method matches the TBi measurements and its ability to detect significant PAD in diabetic patients. Participants will be adults with type 2 diabetes undergoing vascular assessments. Researchers will measure upstroke time with the device and compare it to TBi values. The main outcome is the comparison of these two measurement methods. Participants will be assessed during their routine consultations, and no masking or randomization is involved. The study will complete by December 2026, with ongoing data collection and analysis to understand the diagnostic value of the PPG technique.